Due to its many significant potential benefits, Cannabis and its constituents have been at the forefront of one of the most exciting scientific developments in recent years. Research on the effects of cannabinoids led scientists to the discovery of a previously unknown biochemical communication system in the human body, the Endocannabinoid System (ECS). This system has been shown to play a crucial role in regulating our physiology, mood, and everyday experiences. Endocannabinoid receptors in the brain respond pharmacologically to Cannabis constituents.
The discovery of endogenous cannabinoid compounds in humans that bind to these receptors led to the investigation of Cannabis compounds for their role as an emerging strategy in the modulation of a variety of conditions.
Two primary endocannabinoid receptors have been identified: CB1 in 1990 and CB2 in 1993. These receptors are found predominantly in the brain and nervous system, as well as in peripheral organs and tissues of the immune system. Evidence suggests that endocannabinoids may function as both neuromodulators and immunomodulators in the immune system.
Generally speaking, CB1 signaling mediates neuromodulatory activities, and CB2 signaling mostly mediates immunomodulatory activities. Thus, cannabinoid signaling has been shown to be involved in multiple physiologic and homeostatic systems as well as in pathophysiologic mechanisms.
RESEARCH SUPPORT FOR INFLAMMATORY CONDITIONS AND CHRONIC PAIN
Back thousands of years and more recently, significant research has evaluated the benefit of CBD and other cannabinoids for supporting those with various types of inflammation. Cannabinoids show promise as a new class of inflammation-modulating agents, via their action on cannabinoid receptors in the endocannabinoid system. Cannabinoids modulate the inflammatory response via multiple pathways, including suppression of overactive immune.